EZN-2208
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
SummaryBackground Anti-angiogenic therapies such as bevacizumab upregulate hypoxia-inducible factor-1α (HIF-1α), a possible…
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC
Background: Anti-angiogenic therapies such as…
448 Background: EZN-2208 is a water-soluble, parenterally-delivered PEGylated conjugate of SN38 that increases solubility…
BRCA1 dysfunction in hereditary breast cancer causes defective homology-directed DNA repair and sensitivity towards DNA damaging…
Background EZN-2208 is a water-soluble PEGylated conjugate of SN38 that results in parenteral delivery, increased solubility…
2556 Background: EZN-2208 is a water-soluble, polyethylene glycol (PEG) conjugate of SN38 that is active in solid tumors and…
Purpose: Clinical development of SN38, the active metabolite of camptothecin-11 (CPT-11), has been hampered due to its poor…
Background: The clinical utility of SN38 (10-hydroxy-7-ethyl-camptothecin), the active moiety of CPT-11 (Camptosar®), has been…
1496 Background: SN38 (10-hydroxy-7-ethyl-camptothecin) is the active moiety of CPT-11. Due to its poor solubility, SN38 has not…